Images List Premium Download Classic

Sleep Disorders

Sleep Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
November 30, 2017 - N°20170342103

Where r1, r2, r3, r3′, r4, r6a, r6a, r11a, and r11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (tbi), stress, and epilepsy.
Anti-acth antibodies and use thereof
Alder Biopharmaceuticals, Inc.
November 23, 2017 - N°20170334987

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-acth antibodies and binding fragments thereof conjugated ...
Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of ...
Arena Pharmaceuticals, Inc.
November 09, 2017 - N°20170320831

Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot ...
Sleep Disorders Patent Pack
Download + patent application PDFs
Sleep Disorders Patent Applications
Download + Sleep Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Sleep Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination of valerian root extract and lavender oil for use in the treatment of sleep ...
Merck Canada Inc.
October 19, 2017 - N°20170296612

The present invention relates to a combination of valerian root extract and lavender oil for treating of sleep disorders, as well as to a combination of preparation comprising valerian root extract and lavender oil.
Removable mandibular myo-stimulator
Achaemenid, Llc
October 12, 2017 - N°20170290699

An oral appliance for the treatment of sleep disorders, such as obstructive sleep apnea, in a user is presented. The oral appliance may include a mouthpiece configured to receive a user's dentition. The mouthpiece may include an oxygen sensor, a pressure sensor, an airflow sensor, an actigraphy sensor, a noise detector, and at least one stimulator for providing stimulation to ...
Apparatus and methods for the treatment of sleep apnea
Lumen Devices, Llc
September 21, 2017 - N°20170266034

A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.
Sleep Disorders Patent Pack
Download + patent application PDFs
Sleep Disorders Patent Applications
Download + Sleep Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Sleep Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treating insomnia
Eisai R&d Management Co., Ltd.
September 07, 2017 - N°20170252342

In the present invention, compound such as (1r,2s)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-n-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Neuroactive steroids, compositions, and uses thereof
Sage Therapeutics, Inc.
August 31, 2017 - N°20170247406

Described herein are steroids of formula (i): and pharmaceutically acceptable salts thereof; wherein r1, r2a, r2b, r3, r4, r5a, r5b, r6, and z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, ...
19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
Sage Therapeutics, Inc.
August 31, 2017 - N°20170246191

And pharmaceutically acceptable salts thereof; wherein , r1, r2, r3a, r3b, r4a, r4b, r5, r6, and r7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement ...
Spiro-thiazolones
Sage Therapeutics, Inc.
August 31, 2017 - N°20170246153

Wherein x1, x2, x3, x4, r2, r3, r4, r5, r6 and r7 are as defined herein, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive ...
Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
Universite De Montpellier
August 24, 2017 - N°20170239237

This invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive ...
Prevention or treatment of sleep disorders using dexmedetomidine formulation
Bioxcel Corporation
August 24, 2017 - N°20170239221

There is provided a composition suitable for oral transmucosal administration (sublingual) comprising dexmedetomidine. The composition is useful for the treatment of sleep disorders such as insomnia and capable of providing sleep on demand. The composition comprises an effective amount of dexmedetomidine or pharmaceutically acceptable salts thereof, solvates thereof, or derivatives thereof, formulated for delivery of dexmedetomidine across a subject's oral ...
19-nor neuroactive steroids and methods of use thereof
Bioxcel Corporation
August 17, 2017 - N°20170233432

And pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.
Sleep Disorders Patent Pack
Download + patent application PDFs
Sleep Disorders Patent Applications
Download + Sleep Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Sleep Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery ...
Scientific Partners, Llc
August 10, 2017 - N°20170224911

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood ...
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jazz Pharmaceuticals, Inc.
August 10, 2017 - N°20170224825

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into gbl. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of ghb. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of ...
Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders
Jazz Pharmaceuticals Ireland Limited
July 27, 2017 - N°20170209396

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (ghb). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
Methods and compositions for sleep disorders and other disorders
Intra-cellular Therapies, Inc.
July 06, 2017 - N°20170189398

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-ht2a, sert and/or dopamine d2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or ...
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery ...
Intra-cellular Therapies, Inc.
June 29, 2017 - N°20170182299

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood ...
New uses of ganaxolone
Wisconsin Alumni Research Foundation
June 29, 2017 - N°20170182061

Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in ...
Cardio-kinetic cross-spectral density for assessment of sleep physiology
Lifeq Global Limited
June 29, 2017 - N°20170181691

The invention comprises methods and systems capable of processing simultaneously measured cardiac and motion signals, selecting from said signals the optimal cardiac and motion signal combination for cross spectral density calculations and, hereafter, itemizing the shared information in terms of the individual constituent frequencies and the effect exerted upon said frequencies by common underlying physiological states. The information is passed ...
Botulinum toxin and the treatment of primary disorders of mood and affect
Revance Therapeutics, Inc.
June 15, 2017 - N°20170165331

The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and cns disorders comprising the administration of a neurotoxin.
Loading